Novel HSP90 Inhibitors Effectively Target Functions of Thyroid Cancer Stem Cell Preventing Migration and Invasion

Overview

Journal Surgery

Specialty General Surgery

Date 2015 Nov 7

PMID 26542767

Citations 30

Authors

Peter T White

Chitra Subramanian

Qing Zhu

Huaping Zhang

Huiping Zhao

Robert Gallagher

Barbara N Timmermann

Brian S J Blagg

Mark S Cohen

Affiliations

Soon will be listed here.

Abstract

Background: Thyroid cancer stem cells (CSCs) with ALDH and CD44 markers contribute to tumor growth and aggressiveness. We hypothesized that novel HSP90 inhibitors (KU711, WGA-TA) and 17-AAG can effectively target the function of thyroid CSCs in vitro and prevent migration and invasion.

Methods: Validated papillary (TPC1), follicular (FTC238,WRO), and anaplastic (ACT1) human thyroid cancer cell lines were treated with 3 HSP90 inhibitors. CSCs were quantified for aldehyde dehydrogenase by flow cytometry, CD44 expression by Western blot, and thyrosphere formation assay. Cellular pathway proteins were analyzed by Western blot and migration/invasion by Boyden-chambers.

Results: WGA-TA and 17-AAG induced HSP70 compensation (not observed with KU711) on Western blot in all cell lines (>1,000 fold vs controls). Only WGA-TA degraded HSP90-Cdc37 complexing by 60-70% versus controls. Expression of HSP90 clients β-catenin, BRAF, Akt, and phospho-Akt were significantly inhibited by WGA-TA treatment (50-80%, 50-90%, >80%, and >90%) compared with controls, KU711, and 17-AAG treatment. KU711 and WGA-TA decreased CD44 expression in all cell lines (25-60% vs controls/17-AAG), decreased ALDEFLOR activity by 69-98% (P < .005), and decreased sphere formation by 64-99% (P < .05 each). Finally, cell migration was decreased by 31-98%, 100%, and 30-38%, and invasion by 75-100%, 100%, and 47% by KU711,WGA-TA, and 17-AAG treatment (P < .05) each, respectively.

Conclusion: KU711 and WGA-TA are novel HSP90 inhibitors targeting CSC function and inhibiting cell migration/invasion in differentiated and anaplastic thyroid cancers, warranting further translational evaluation in vivo.

Citing Articles

Application of machine learning for mass spectrometry-based multi-omics in thyroid diseases.

Che Y, Zhao M, Gao Y, Zhang Z, Zhang X Front Mol Biosci. 2025; 11:1483326.

PMID: 39741929 PMC: 11685090. DOI: 10.3389/fmolb.2024.1483326.

Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.

Wang J, Tan J, Wu B, Wu R, Han Y, Wang C J Nanobiotechnology. 2023; 21(1):374.

PMID: 37833748 PMC: 10571362. DOI: 10.1186/s12951-023-02094-9.

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.

Lundgren Mortensen A, Berglund H, Hariri M, Papalanis E, Malmberg C, Spiegelberg D Sci Rep. 2023; 13(1):16844.

PMID: 37803074 PMC: 10558458. DOI: 10.1038/s41598-023-43486-z.

circSLC4A7 accelerates stemness and progression of gastric cancer by interacting with HSP90 to activate NOTCH1 signaling pathway.

Hui Y, Wenguang Y, Wei S, Haoran W, Shanglei N, Ju L Cell Death Dis. 2023; 14(7):452.

PMID: 37474578 PMC: 10359325. DOI: 10.1038/s41419-023-05976-w.

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).

Li Z, Luo Y Oncol Rep. 2022; 49(1).

PMID: 36367182 PMC: 9685368. DOI: 10.3892/or.2022.8443.

References

Sidera K, Patsavoudi E . HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2013; 9(1):1-20. View

Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria V . Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics. 2011; 12 Suppl 1:S30. PMC: 3044286. DOI: 10.1186/1471-2105-12-S1-S30. View

Kakar S, Jala V, Fong M . Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines. Biochem Biophys Res Commun. 2012; 423(4):819-25. PMC: 3402232. DOI: 10.1016/j.bbrc.2012.06.047. View

Yu T, Chen X, Zhang W, Colon D, Shi J, Napier D . Regulation of the potential marker for intestinal cells, Bmi1, by β-catenin and the zinc finger protein KLF4: implications for colon cancer. J Biol Chem. 2011; 287(6):3760-8. PMC: 3281718. DOI: 10.1074/jbc.M111.316349. View

Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S . Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007; 13(4):1161-70. DOI: 10.1158/1078-0432.CCR-06-1125. View

Shimamura M, Nagayama Y, Matsuse M, Yamashita S, Mitsutake N . Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines. Endocr J. 2014; 61(5):481-90. DOI: 10.1507/endocrj.ej13-0526. View

Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O . Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999; 18(3):813-22. DOI: 10.1038/sj.onc.1202367. View

Sherman S . Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22(6):464-8. DOI: 10.1016/j.clon.2010.03.014. View

Lee J, Hahm E, Marcus A, Singh S . Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Mol Carcinog. 2013; 54(6):417-29. PMC: 4039625. DOI: 10.1002/mc.22110. View

10.

Grogan P, Sleder K, Samadi A, Zhang H, Timmermann B, Cohen M . Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs. 2012; 31(3):545-57. PMC: 3677827. DOI: 10.1007/s10637-012-9888-5. View

11.

Marcu M, Chadli A, Bouhouche I, Catelli M, Neckers L . The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000; 275(47):37181-6. DOI: 10.1074/jbc.M003701200. View

12.

Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli J . Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006; 91(8):2892-9. DOI: 10.1210/jc.2005-2838. View

13.

Zhao J, Zhao H, Hall J, Brown D, Brandes E, Bazzill J . Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm. 2014; 5(9):1317-1323. PMC: 4198308. DOI: 10.1039/C4MD00102H. View

14.

Pak K, Suh S, Kim S, Kim I . Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid. 2014; 25(1):63-70. DOI: 10.1089/thy.2014.0241. View

15.

Park J, Yeh M, Wong M, Lobo M, Hyun W, Duh Q . The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab. 2003; 88(7):3346-53. DOI: 10.1210/jc.2002-020340. View

16.

Motiwala H, Bazzill J, Samadi A, Zhang H, Timmermann B, Cohen M . Synthesis and Cytotoxicity of Semisynthetic Withalongolide A Analogues. ACS Med Chem Lett. 2013; 4(11). PMC: 3835334. DOI: 10.1021/ml400267q. View

17.

Zhao H, Donnelly A, Kusuma B, Brandt G, Brown D, Rajewski R . Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J Med Chem. 2011; 54(11):3839-53. PMC: 3164572. DOI: 10.1021/jm200148p. View

18.

Shoup M, Stojadinovic A, Nissan A, Ghossein R, Freedman S, Brennan M . Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003; 197(2):191-7. DOI: 10.1016/S1072-7515(03)00332-6. View

19.

Bhatia P, Tsumagari K, Abd Elmageed Z, Friedlander P, Buell J, Kandil E . Stem cell biology in thyroid cancer: Insights for novel therapies. World J Stem Cells. 2014; 6(5):614-9. PMC: 4178261. DOI: 10.4252/wjsc.v6.i5.614. View

20.

Hahm E, Moura M, Kelley E, Van Houten B, Shiva S, Singh S . Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One. 2011; 6(8):e23354. PMC: 3154436. DOI: 10.1371/journal.pone.0023354. View